Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
Study Details
Study Description
Brief Summary
The purpose of this study is to assess an effective single oral supplement or combination of oral supplements for increasing whole blood NAD+ levels.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a open-label dose finding study to detect an effective single oral supplement or combination of oral supplements for enhancing whole blood levels of NAD+. Each subject will receive a specific dose of the formulation once daily for 3 days followed by a washout period. Upon completion of the treatment phase, there is a post-treatment period of assessments.
Participants receive assessments of blood tests, vital signs, body weight with completion of questionnaires.
The primary objective of the study is to identify the ideal dosage of an oral supplement to increase whole blood NAD+ levels in adults.
The secondary objective of the study is to monitor for safety from a change in fasting blood chemistry panel parameters after three day's dosing compared to cycle baseline.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort A (oral supplement A)-2 capsules Oral supplement A (2 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Other Names:
|
| Experimental: Cohort A (oral supplement B)-4 capsules Oral supplement B (4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement B
4 capsules daily of oral supplement B for 3 days
Other Names:
|
| Experimental: Cohort A (oral supplement C)-2 capsules Oral supplement C (2 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Other Names:
|
| Experimental: Cohort A (oral supplement A)-1 or 4 capsules Oral supplement A (1 or 4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Other Names:
|
| Experimental: Cohort A (oral supplement D)-1 or 2 tablets Oral supplement D (1 or 2 tablets) administered daily for 3 days |
Dietary Supplement: Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Other Names:
|
| Experimental: Cohort A (oral supplement D) or combination with supplement C Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Other Names:
Dietary Supplement: Oral Supplement D in combination with oral supplement C
1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
|
| Experimental: Cohort B (oral supplement B)-4 capsules Oral supplement B (4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement B
4 capsules daily of oral supplement B for 3 days
Other Names:
|
| Experimental: Cohort B (oral supplement C)-2 capsules Oral supplement C (2 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Other Names:
|
| Experimental: Cohort B (oral supplement A)-2 capsules Oral supplement A (2 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Other Names:
|
| Experimental: Cohort B (oral supplement C)- 1 or 4 capsules Oral supplement C (1 or 4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Other Names:
|
| Experimental: Cohort B (oral supplement D)-1 or 2 tablets Oral supplement D (1 or 2 tablets) administered daily for 3 days |
Dietary Supplement: Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Other Names:
|
| Experimental: Cohort B(oral supplement D) or combination with supplement C Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days |
Dietary Supplement: Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Other Names:
Dietary Supplement: Oral Supplement D in combination with oral supplement C
1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
|
Outcome Measures
Primary Outcome Measures
- Assess the mean change in NAD+ levels from baseline [63 days]
Mean change in NAD+ levels
Secondary Outcome Measures
- Assess the mean change in AST (aspartate aminotransferase) levels from baseline [63 days]
Mean change in AST level
- Assess the mean change in ALT (alanine aminotransferase) levels from baseline [63 days]
Mean change in ALT level
- Assess the mean change in Total Cholesterol levels from baseline [63 days]
Mean change in Total Cholesterol level
- Assess the mean change in Triglycerides levels from baseline [63 days]
Mean change in Triglycerides level
- Assess the mean change in LDL Cholesterol levels from baseline [63 days]
Mean change in LDL Cholesterol level
- Assess the mean change in HDL Cholesterol levels from baseline [63 days]
Mean change in HDL Cholesterol level
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able to provide written Informed Consent
-
Able to follow verbal and written study directions in English
-
Adult men and women between age 30-80 years (inclusive)
-
Women of reproductive potential will practice contraception during the Investigation
-
Body Mass Index (BMI) between 18.5 and 35 kg/m2
-
Must not be taking or be willing to stop taking any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
-
Must not be using or be willing to stop use of any "100%" or higher niacin fortified foods from seven days prior to screening visit and for the duration of the investigation
-
Able to maintain consistent diet and lifestyle habits throughout the study
-
Volunteers with chronic but stable and well controlled medical conditions (i.e., hypertension controlled by a consistent dose of medication for a minimum of six months; chronic use of consistent dose of blood-thinning medication; diet-controlled Type II diabetes) may participate at the discretion of the PI or Sub-I.
-
Willing and able to provide fasting blood samples
-
Able to attend scheduled visits at the Life Extension Clinical Research (LECR) facility
Exclusion Criteria:
-
Current use of prescription or over-the-counter nicotinic acid
-
Use of statin drugs
-
Having used any tobacco product or used a recreational drug in the past 6 months
-
Medically complicated [i.e., diabetes requiring insulin; uncontrolled hypertension (blood pressure readings at screening/baseline > 140 systolic or > 90 diastolic on two consecutive readings); etc.] at the discretion of the PI or Sub-I
-
Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the PI or Sub-I
-
Woman who is pregnant, nursing, or planning a pregnancy. Non-pregnant status of women of childbearing potential will be confirmed during each Day 3 Cycle LECR visit (Wednesday or Thursday) via serum pregnancy test.
-
Currently, or within the past 30 days, enrolled in a different clinical investigation
-
Inability to provide a venous blood sample
-
Unable to refrain from any alcohol consumption for the duration of the study
-
Unable or unwilling to provide written informed consent for participation in study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Life Extension Clinical Research, Inc. | Fort Lauderdale | Florida | United States | 33308 |
Sponsors and Collaborators
- Supplement Formulators, Inc.
Investigators
- Principal Investigator: Andrew Swick, Ph.D, LIfe Extension
Study Documents (Full-Text)
None provided.More Information
Publications
- Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017 Dec 6;12(12):e0186459. doi: 10.1371/journal.pone.0186459. eCollection 2017.
- ClinicalTrials.gov. Effect of
- de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016 Jun;15(3):522-30. doi: 10.1111/acel.12461. Epub 2016 Mar 11.
- Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017 Nov 24;3:17. doi: 10.1038/s41514-017-0016-9. eCollection 2017. Erratum in: NPJ Aging Mech Dis. 2018 Aug 20;4:8.
- Gross CJ, Henderson LM. Digestion and absorption of NAD by the small intestine of the rat. J Nutr. 1983 Feb;113(2):412-20.
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998.
- Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, Pessin JE, Rando TA, Richardson A, Schadt EE, Wyss-Coray T, Sierra F. Geroscience: linking aging to chronic disease. Cell. 2014 Nov 6;159(4):709-13. doi: 10.1016/j.cell.2014.10.039.
- Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia. 2000 Nov;43(11):1337-45. Review.
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi: 10.1371/journal.pone.0042357. Epub 2012 Jul 27.
- Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016 Dec 13;24(6):795-806. doi: 10.1016/j.cmet.2016.09.013. Epub 2016 Oct 27.
- Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 2007 Mar;23(2):164-70. Review.
- Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.
- Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4;350(6265):1208-13. doi: 10.1126/science.aac4854. Review.
- Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol. 2006 Aug;41(8):718-26. Epub 2006 Jul 13. Review.
- CL094